Johnson & Johnson (NYSE:JNJ) Shares Sold by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 1.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 300,753 shares of the company’s stock after selling 3,451 shares during the period. Johnson & Johnson makes up about 1.6% of Daymark Wealth Partners LLC’s investment portfolio, making the stock its 13th biggest holding. Daymark Wealth Partners LLC’s holdings in Johnson & Johnson were worth $48,740,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the stock. Saxon Interests Inc. lifted its position in shares of Johnson & Johnson by 14.8% during the third quarter. Saxon Interests Inc. now owns 6,823 shares of the company’s stock worth $1,106,000 after purchasing an additional 880 shares in the last quarter. Safir Wealth Advisors LLC acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $220,000. Peddock Capital Advisors LLC lifted its holdings in Johnson & Johnson by 1.3% in the 3rd quarter. Peddock Capital Advisors LLC now owns 9,935 shares of the company’s stock worth $1,610,000 after buying an additional 127 shares in the last quarter. Greenhouse Wealth Management LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at about $215,000. Finally, Tilia Fiduciary Partners Inc. increased its position in shares of Johnson & Johnson by 2.8% during the third quarter. Tilia Fiduciary Partners Inc. now owns 3,230 shares of the company’s stock worth $523,000 after acquiring an additional 89 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $0.42 during trading hours on Wednesday, hitting $160.11. 924,698 shares of the company’s stock traded hands, compared to its average volume of 7,033,937. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The company’s fifty day simple moving average is $162.59 and its two-hundred day simple moving average is $154.36. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The company has a market cap of $385.33 billion, a price-to-earnings ratio of 9.98, a price-to-earnings-growth ratio of 2.69 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.80 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.10%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Royal Bank of Canada lifted their target price on Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a research report on Tuesday. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, September 30th. The Goldman Sachs Group cut their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Finally, Sanford C. Bernstein raised their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.43.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.